KLK3 and prostate carcinoma: Therefore, even though E4G10 did not bind to the LNCap tumors directly, treatment with 225Ac-labeled E4G10 resulted in an inhibition of tumor growth, lower serum PSA and enhanced survival in prostate cancer xenograft-bearing mice.